Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Gains from Sales and Divestitures (2020 - 2025)

Catheter Precision (VTAK) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $11263.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $11263.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $11263.0, a N/A change, with the full-year FY2023 number at $26.0, down 77.78% from a year prior.
  • Gains from Sales and Divestitures was $11263.0 for Q3 2025 at Catheter Precision, down from $100000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $100000.0 in Q2 2025 to a low of $26.0 in Q1 2023.
  • A 4-year average of $18394.7 and a median of $3966.5 in 2022 define the central range for Gains from Sales and Divestitures.
  • Biggest YoY gain for Gains from Sales and Divestitures was 1953.71% in 2023; the steepest drop was 99.61% in 2023.
  • Catheter Precision's Gains from Sales and Divestitures stood at $625.0 in 2021, then crashed by 81.28% to $117.0 in 2022, then plummeted by 77.78% to $26.0 in 2023, then soared by 43219.23% to $11263.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Gains from Sales and Divestitures are $11263.0 (Q3 2025), $100000.0 (Q2 2025), and $49999.0 (Q1 2025).